| Home : April 2015 : April 10, 2015 News : U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults |
U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults |
April 10, 2015
LEXINGTON, Massachusetts, April 9, 2015 /PRNewswire/ --
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lifitegrast and granted a Priority Review designation....
http://www.prnewswire.com/news-releases/us-fda-grants-priority-review-to-lifitegrast-nda-for-the-treatment-of-dry-eye-disease-in-adults-499218521.html
|
|
|
 Other Stories |
|
|
|
|
|
|
|
|
|
|
|
